Karyopharm Therapeutics (FRA:25K) Pre-Tax Income : €-134.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Karyopharm Therapeutics's pretax income for the three months ended in Mar. 2024 was €-34.3 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was €-134.9 Mil. Karyopharm Therapeutics's pretax margin was -112.57%.

During the past 13 years, Karyopharm Therapeutics's highest Pretax Margin was -59.01%. The lowest was -71063.64%. And the median was -538.00%.

Karyopharm Therapeutics Pre-Tax Income Historical Data

The historical data trend for Karyopharm Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Pre-Tax Income Chart

Karyopharm Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-179.60

-161.08

-109.58

-155.69

-130.93

Karyopharm Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Pre-Tax Income	Get a 7-Day Free Trial															-31.82	-30.00	-32.32	-38.25	-34.31

Competitive Comparison of Karyopharm Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Karyopharm Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karyopharm Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Pre-Tax Income falls into.

Karyopharm Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Karyopharm Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-118.788	+	-0.326	+	-21.846	+	10.035	+	-0.0010000000000048
	=	-130.9

Karyopharm Therapeutics's Pretax Income for the quarter that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-31.058	+	0.18	+	-5.413	+	1.984	+	-0.00099999999999767
	=	-34.3

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-134.9 Mil.

Karyopharm Therapeutics (FRA:25K) Pre-Tax Income Explanation

Karyopharm Therapeutics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-34.308	/	30.476
	=	-112.57%

During the past 13 years, Karyopharm Therapeutics's highest Pretax Margin was -59.01%. The lowest was -71063.64%. And the median was -538.00%.

Karyopharm Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics (FRA:25K) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

KPTI:USA

Address

85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459

Website

https://www.karyopharm.com

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (FRA:25K) Headlines

No Headlines